- Home
- ZEPP vs AGEN Comparison
ZEPP vs AGEN Comparison
Compare ZEPP & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEPP
- AGEN
- Stock Information
- Founded
- ZEPP 2013
- AGEN 1994
- Country
- ZEPP China
- AGEN United States
- Employees
- ZEPP N/A
- AGEN N/A
- Industry
- ZEPP Computer Manufacturing
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZEPP Technology
- AGEN Health Care
- Exchange
- ZEPP Nasdaq
- AGEN Nasdaq
- Market Cap
- ZEPP 37.0M
- AGEN 38.1M
- IPO Year
- ZEPP N/A
- AGEN 2000
- Fundamental
- Price
- ZEPP $2.56
- AGEN $2.08
- Analyst Decision
- ZEPP
- AGEN Buy
- Analyst Count
- ZEPP 0
- AGEN 4
- Target Price
- ZEPP N/A
- AGEN $8.00
- AVG Volume (30 Days)
- ZEPP 25.8K
- AGEN 439.0K
- Earning Date
- ZEPP 05-19-2025
- AGEN 05-06-2025
- Dividend Yield
- ZEPP N/A
- AGEN N/A
- EPS Growth
- ZEPP N/A
- AGEN N/A
- EPS
- ZEPP N/A
- AGEN N/A
- Revenue
- ZEPP $182,603,000.00
- AGEN $103,463,000.00
- Revenue This Year
- ZEPP $758.69
- AGEN $4.03
- Revenue Next Year
- ZEPP N/A
- AGEN $5.57
- P/E Ratio
- ZEPP N/A
- AGEN N/A
- Revenue Growth
- ZEPP N/A
- AGEN N/A
- 52 Week Low
- ZEPP $2.06
- AGEN $1.38
- 52 Week High
- ZEPP $4.38
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- ZEPP 44.08
- AGEN 57.30
- Support Level
- ZEPP $2.20
- AGEN $1.60
- Resistance Level
- ZEPP $2.66
- AGEN $1.83
- Average True Range (ATR)
- ZEPP 0.24
- AGEN 0.19
- MACD
- ZEPP -0.02
- AGEN 0.08
- Stochastic Oscillator
- ZEPP 42.48
- AGEN 94.59
About ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in two segments: Xiaomi Wearable Products and Self-branded products & others. The product portfolio includes smartwatches and fitness bands. The majority is from Self-branded products & other segments. It generates majority of the revenue from Xiaomi Wearable Products segment.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).